IMPORTANCE Neuroinflammation appears to be a key modulator of disease progression in amyotrophic lateral sclerosis (ALS) and thereby a promising therapeutic target. The CD4 + Foxp3 + regulatory T-cells (Tregs) infiltrating into the central nervous system suppress neuroinflammation and promote the activation of neuroprotective microglia in mouse models of ALS. To our knowledge, the therapeutic association of host Treg expansion with ALS progression has not been studied in vivo.
N euroinflammation is a pathological hallmark of amyotrophic lateral sclerosis (ALS), 1 a progressive and fatal neurodegenerative disorder caused by loss of upper and lower motor neurons. 2 Accumulating evidence suggests that astrocytes, microglia, and T-cells actively contribute to neurodegeneration and disease progression in ALS. 3, 4 Reducing ALS-linked mutant superoxide dismutase 1 (SOD1) synthesis in microglia 5 or astrocytes 6 has been shown to slow disease progression, while elimination of CD4 + T-cells has been shown to accelerate symptom severity in mice with a mutant form of the SOD1 gene. 7, 8 Peripheral blood cells and astrocytes generated from fibroblasts of patients with ALS are also toxic to motor neurons.
9,10
Consequently, nonneuronal cell toxicity contributes to neurodegeneration in ALS through non-cell autonomous mechanisms.
11
During early disease stages in mice with a mutant form of SOD1, CD4 + Foxp3 + regulatory T-cells (Tregs) accumulate in blood and lymph nodes, while spinal cord messenger RNA (mRNA) expression of Foxp3, a key transcriptional regulator of Tregs, 12 is induced. In concert, anti-inflammatory cytokines are upregulated, resulting in microglia exhibiting a neuroprotective M2 (alternatively activated) phenotype that provides neurotrophic support. 13 With disease progression, proinflammatory cytokine levels increase and microglia transition to a neurotoxic M1 (classically activated) phenotype, while Treg levels decline. 13 In patients with ALS, there are reduced levels of CD4 + T-cells, 14 increased proportions of proinflammatory effector T-cells, 15 ,16 increased macrophage activation, 17 and upregulated costimulatory pathways, 18 while reduced Treg numbers are associated with rapid disease course. 19 Interestingly, adoptive transfer of Tregs in mice with a mutant form of SOD1 induces M2 microglia in the spinal cord and prolongs survival time, 13, 20 suggesting that Tregs contribute to neuroprotection by modulating microglial activation. It is now apparent from studies in mouse models that Tregs can undergo further differentiation in the peripheral lymphoid organs into a population termed effector Tregs, which express a distinct set of molecules important for Treg function. 21 To determine whether enhancement of Tregs frequency and effector function was associated with a slower rate of disease progression in ALS, this study initially undertook comprehensive Treg immunophenotyping that, to our knowledge, has not previously been undertaken in patients mouse is a transgenic murine model with a G93A mutant form of SOD1 that results in motor neuron degeneration analogous to human amyotropic lateral sclerosis. The aim of this study is to better understand the pathophysiological processes by which Treg expansion mediated neuroprotective effects in ALS.
Methods

Ethics Statement
Human studies were approved by the Western Sydney Local Health District human research ethics committee, and all patients provided written informed consent prior to recruitment into the study. All mouse experiments conformed to the Australian National Health and Medical Research Council Code of Practice 39 and were approved by the Howard Florey Institute animal ethics committee.
Data Collection From Human Participants
Venous blood was collected in EDTA with informed consent from 33 patients who had been diagnosed as having possible, probable, or definite ALS according to the revised El Escorial criteria, 26 as well as 38 age-matched healthy control participants recruited consecutively from the ALS clinic at Westmead Hospital in Westmead, Australia, between February 1, 2013, and December 31, 2014. (No participants declined to be involved in the study.) The sample size was based on a calculation of 80% power necessary to detect a correlation of whole-blood levels of Foxp3 with disease progression. 19 At the time of blood collection, all patients were clinically staged using the revised ALS Functional Rating Scale (ALSFRS-R), 27 which correlates well with survival time.
28
Full blood cell counts were performed at the Westmead Hospital diagnostic laboratory for determination of lymphocyte counts per milliliter. Peripheral blood mononuclear cells were isolated on Ficoll-Paque Plus media (VWR International), washed in phosphate-buffered saline, and cryopreserved in Roswell Park Memorial Institute 1640 medium (Life Technologies) containing 2000μM glutamine, 10% heatinactivated fetal bovine serum, 10% dimethyl sulfoxide, 50 units/mL of penicillin, and 50 μg/mL of streptomycin.
The details of flow cytometry and antibodies used in human samples are outlined in the eMethods in the Supplement. Briefly, antibodies to human antigens used were monoclonal antibodies to CD25 (clone BC96), CD4 (RPA-T4), CD31 (WM59), and a corresponding isotype control (IgG1; all from BioLegend); CD45RA (clone HI100) and CD45RO (clone UCHL1; both from BD Pharmingen); and CD127 (clone eBioRDR5) and
Key Points
Question Are regulatory T-cells associated with a slower rate of disease progression in amyotrophic lateral sclerosis?
Findings In this study, the expansion of endogenous regulatory T-cells in a mouse model of amyotrophic lateral sclerosis significantly prolonged survival time and was associated with preserved motor neuron soma size, marked suppression of glial cell immunoreactivity, and increased neuroprotective gene-expression profiles. Regulatory T-cells were also shown to correlate with a slower rate of disease progression in patients with amyotrophic lateral sclerosis.
Meaning Therapies aimed at modulating regulatory T-cells in patients with amyotrophic lateral sclerosis may prove therapeutically beneficial.
FoxP3 (clone 236A/E7; both from eBioscience). Peripheral blood mononuclear cells were thawed, washed in Roswell Park Memorial Institute medium with 2% fetal bovine serum, and incubated for 30 minutes in the medium with 10mM HEPES, 1mM magnesium chloride, and 100 units/mL of DNase I (Roche Pharmaceuticals). Cells were blocked with mouse IgG (33 μg/mL) and stained for extracellular antigens (or, in the case of CD31, fluorescence minus 1 IgG control) followed by fixation, permeabilization, and staining for Foxp3 using the Foxp3 Staining Buffer Set (eBioscience). Cells were analyzed by flow cytometry on an FACS Canto II system (BD Biosciences).
Data Collection From Animal Participants
Given that the current clinical data demonstrated a correlation between Treg levels and disease progression in patients with ALS, we aimed to determine whether expansion of a murine-activated effector Treg phenotype (which was similar to the human Treg phenotype) was associated with a slower rate of disease progression and prolonged survival time in the SOD1 G93A mouse model. Specifically, the endogenous Treg population in SOD1 G93A mice was amplified by using the IL-2/ IL-2 monoclonal antibody complexes (IL-2c) at 60 days of age. Transgenic SOD1 G93A mice derived from the B6SJL-TgN (SOD1*G93A) 1Gur/J line (Jackson Laboratory) were backcrossed 12 generations and maintained on a pure C57BL/6 genetic background. Male mice were divided into 3 groups with equal litter contribution: IL-2/IL-2c, 1 μg/5 μg, plus rapamycin, 1 mg/kg (Millipore); rapamycin alone; or vehicle (dimethyl sulfoxide or phosphate-buffered saline) alone. Mouse IL-2 carrier-free recombinant protein and functionalgrade purified IL-2 monoclonal antibody (of the JES6-1A12 clone) were both obtained from eBioscience (Jomar Life Research). Importantly, the IL-2/IL-2 monoclonal antibody complex increases the biological activity of the T-cell growth factor IL-2, and the JES6-1 monoclonal antibody clone confers specificity to cells expressing high-affinity αβγ IL-2R (CD25 The IL-2c protein was prepared weekly, as previously described. 24 Briefly, IL-2 and IL-2 monoclonal antibodies were mixed and incubated at 37°C for 30 minutes. Starting from a postnatal age of 60 days, mice were intraperitoneally injected with 100 μL of the mixture once a day for 3 days, followed by twice-weekly maintenance injections. All mice received 2 daily injections of rapamycin or 0.1% dimethyl sulfoxide (vehicle) in the morning, followed by either IL-2c or phosphate-buffered saline (vehicle), respectively, in the afternoon. (Injections occurred at least 5 hours apart.) The numbers of Tregs in blood were determined by flow cytometry at 100 days of age. (Representative gating for Treg markers is shown in eFigure 1 in the Supplement.) In addition, we carried out immunohistochemical assessments of glucocorticoid-induced tumor necrosis factor receptorrelated (GITR) protein, cytotoxic T-lymphocyte antigen 4 (CTLA4), and inducible T-cell costimulator (ICOS), which contribute to the suppressive phenotype of Tregs because IL-2c is known to induce expression of these immune checkpoint molecules.
32-34
Age-matched wild-type mice of the C57BL/6 genetic background were used as controls for flow cytometry and immunohistochemistry. Mice were killed by an intraperitoneal lethal injection of sodium pentobarbitone, 100 mg/kg. (We observed mild thinning of coat fur around the injection site in all mice treated long term with IL-2c, and a subgroup of these mice developed spleen atrophy.)
The investigators were blinded to the identities of treatment groups. The details of flow cytometry, quantitative reverse-transcription polymerase chain reaction, behavioral analysis, histology, and immunohistochemistry are outlined in the eMethods in the Supplement. Briefly, we correlated the expression of Foxp3, Th2 activation marker Gata3, M2 markers Retnla/Fizz1, and glial-cell-derived growth factor with Tregs in the spinal cords of IL-2c-treated SOD1 G93A mice and vehicletreated SOD1 G93A mice. We further investigated Treg-induced modulation of disease through assessments of glial fibrillary acidic protein (GFAP) immunoreactivity and cluster of differentiation molecule 11b (CD11b) immunoreactivity in SOD1 G93A mice and wild-type mice.
Statistical Analysis
Human data were analyzed with Mann-Whitney tests to compare nonparametric data on participants with ALS with control participants. The rate of disease progression was calculated as a change in ALSFRS-R, 29 and Pearson correlations of disease progression and age with Treg frequency (or log e Treg for normalization) were calculated. After flow cytometry, CD4 subsets were determined as a percentage of all lymphocytes gated using forward and side scatter, and as a percentage of all leukocytes by dual-platform analysis using full blood cell counts from the same blood collection. Mouse flow cytometry data, motor neuron areas, and glial immunohistochemistry were analyzed using 1-way analysis of variance with Tukey multiple-comparison test. Disease onset and quantitative polymerase chain reaction data were analyzed using an unpaired t test. Survival data were analyzed using Kaplan-Meier survival analysis with the log-rank test. All analyses except flow cytometry were performed using GraphPad Prism software, version 6.0 (GraphPad Software Inc). Flow cytometry used FlowJo software (Treestar Inc).
Results
Comparison of Tregs in Patients With ALS and Control Participants
The clinical and demographic features of patients with ALS (n = 33) and healthy control participants (n = 38) are summarized in the 
Tregs and Rate of ALS Progression
The rate of progression in patients with ALS was inversely correlated with total Treg counts (R = −0.40; P = .02; eTable 2 in the Supplement), total Foxp3 + Treg (R = −0.41; P = .02; Figure 1A ) and effector (CD45RO + ) Foxp3 + Tregs counts;
(R = −0.39; P = .02; Figure 1B ), as well as CD4 + lymphocyte counts (R = −0.36; P = .04; Figure 1C ). There was a significant correlation of disease progression rate with absolute counts for each of these subsets (eTable 2 in the Supplement). In contrast, resting (CD45RA + ) Foxp3 + Tregs were not correlated with the rate of disease progression (R = −0.20; P = .26; Figure 1D Figure 2A ). It is also known that IL-2c induces expression of glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), cytotoxic T-lymphocyte antigen 4 (CTLA4), and inducible T-cell costimulator (ICOS), which contribute to the suppressive phenotype of Tregs.
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There was a significant mean (SD) increase of GITR Figure 2E ). There was a trend for improved motor function evidenced by rotarod analysis of SOD1 G93A mice treated with IL-2c ( Figure 2F ). Disease onset, as determined by body weight decline, was not impacted by Treg expansion ( Figure 2G ). This is consistent with a role of Tregs in mediating disease course, but not initiation of ALS.
IL-2c and T-Cell Recruitment to the Spinal Cords of Mutant SOD1 Mice
To confirm the presence of Tregs in the spinal cords of mice, we examined tissue using immunohistochemistry. We did not detect CD3 + T-cells in the lumbar spinal cords of wild-type mice as expected ( Figure 3A Figure 3K , L, M, and T). Pronounced activation of GFAP + astrocytes (which encode glial fibrillary acidic protein) and CD11b + microglia was observed in the spinal cords of vehicle-treated SOD1 G93A mice, but not in wild-type control mice ( Figure 3N , O, P, Q, R, and S Figure 3V ). These data support the notion that endogenous effector Treg 
IL-2c Treatment and Neurotrophic Response in the Spinal
Discussion
A growing body of evidence points to the immune response as a powerful modulator of disease activity in ALS, integral to neuroprotection. 36 While this holds great promise as a therapeutic target, generalized immunosuppression has not exerted any effects on disease progression in ALS, 37 thereby suggesting that targeted immunoregulation may be required. The findings in the present study establish an inverse correlation between comprehensively phenotyped Treg counts and rate G93A mice (n = 5) at 100 days of age. A, Differences were significant between vehicle-treated and IL-2c-treated SOD1 G93A G93A mice (n = 10) was significantly prolonged compared with the vehicle-treated group (n = 9). Survival was defined by onset of hind-limb paralysis. Significance was determined using Kaplan-Meier survival analysis with the log-rank test. F, Rotarod performance. G, Disease onset as determined by the onset of weight loss was not affected by IL-2c treatment.
of disease progression, suggesting the importance of Tregs in ALS pathogenesis.
Underscoring the pathogenic importance of Tregs in ALS are findings of prolonged survival in SOD1 G93A mice treated with IL-2c that specifically expands the number of effector Tregs, with accompanying anti-inflammatory changes within the central nervous system. Consequently, modulation of the immune system in patients with ALS, particularly enhancement of regulatory T-cell function, may prove therapeutically useful in ALS treatment.
Regulatory T-Cells and ALS Pathogenesis
Tregs appear to be important in ALS pathogenesis, particularly in regulating the rate of disease progression. 13 Specifically, an inverse correlation between disease progression rates and Treg levels was previously reported, 13 and a follow-up study by the same group showed that levels of the Treg transcription factor Foxp3 in blood was predictive of progression rate and survival. 19 Using a different functional scoring system (the ALSFRS-R 27 rather than the Appel score 13 ), and more comprehensive immunophenotyping, the present study provides independent replication of previous findings, confirming an inverse correlation between disease progression rate with Tregs 13,19 and with total CD4 + asaproportion of leukocytes. Of further relevance is a significant correlation of disease progression rate with the CD45RO + effector subset of Tregs that expressed very high levels of Foxp3, but not the CD45RA + resting subset that were Foxp3 lo . This was a novel finding in the present study. Unlike CD45RO + conventional T-cells, memory or recall response has not been demonstrated for Tregs, and CD45RO is a marker of activation and functional differentiation of Tregs that correlates with high expression of CTLA4, which mediates contact-dependent suppression, and GITR.
12
These results suggest a correlation of reduced disease progression rate with the potent immunosuppressive activity of activated Tregs. 12 Others have demonstrated that, in patients with ALS, with a rapid progression rate, reduction in peripheral Treg levels parallels the reductions in Foxp3 in the spinal cord, 19 thereby suggesting that a systemic deficit of Tregs, rather than recruitment to the central nervous system, may explain the peripheral Treg deficits in rapidly progressing ALS. Interestingly, CD45RO + Tregs are highly susceptible to apoptosis compared with CD45RA+ following activation and suppression. 12 We hypothesize that activation-induced apoptosis may lead to the selective depletion of activated Tregs in rapidly progressive ALS, possibly because of greater Treg activation in a more inflammatory environment and greater disease-related cellular stress conferring a higher propensity to activation-induced cell death.
In contrast, resting CD45RA + Treg subsets were not correlated with the rate of disease progression, a finding not previously reported. Instead, CD45RA + Treg subsets were correlated with age of patients with ALS (an association that was stronger for the CD31 + subsets enriched for recent thymic emigrants), 38 but naive CD45RA + T-cells were not correlated with patient age. This is consistent with the previously reported age-related decline in CD45RA + Tregs and could be attributed to thymic involution with age, a selective reduction in thymic output of Tregs with age, or reduced lifespan of Tregs in the periphery. 31 Further studies are required to determine whether the exaggerated decline of resting Tregs with age in patients with ALS is of pathogenic importance.
Limitations
A potential limitation of this study pertains to the crosssectional design. Although there was a correlation between disease progression and Treg activity in patients with ALS, which suggests a neuroprotective effect and is confirmed by animal studies, the correlation does not establish causality.
Longitudinal studies in patients with ALS would be important because they could potentially shed light on effects of disease progression on the regulatory immune system and vice versa.
Conclusions
The present study provides strong support for a neuroprotective role of Tregs in patients with ALS, whereby enhanced Treg activity is associated with a slower rate of disease progression. Expansion and differentiation of endogenous Tregs in SOD1 G93A mice by the biological agent IL-2c led to a significant reduction of glial activation, a shift to neuroprotective autoimmunity, and neurotrophic effects at the spinal cord level. The molecular and pathological changes were associated with significantly prolonged survival in the SOD1 G93A mouse model, a finding likely explained by a slowing of disease progression. Strategies aimed at enhancing Treg function could prove therapeutically useful in patients with ALS. 
Behavioural analysis
Body weight and locomotor function of mice were analysed weekly from P60 using an accelerating Mouse Rota-Rod 47600 (Ugo Basile, Monvalle, Italy). At P60, vehicle (n = 9) and IL-2c (n=10) mice were trained on the rotarod by performing a 5 min session at a constant speed (20 rpm), followed by two 5 min session at accelerating speed (4-40 rpm) with 10 min rest periods between each training session. The following day, mice
were tested twice at 4-40 rpm (5 min) and the average latency to fall recorded. Age of disease onset and onset of motor dysfunction were determined using the age of peak body weight and rotarod performance, respectively, as previously described 2 . For survival analysis, mice were killed by lethal injection at disease endstage which was objectively determined by the onset of hindlimb paralysis.
Histology and immunohistochemistry
Mice were transcardially perfused using PBS and then cold 4% paraformaldehyde (PFA) in 0.1M phosphate 
